標題: Titlebook: Congenital Bleeding Disorders; Diagnosis and Manage Akbar Dorgalaleh Book 2023Latest edition The Editor(s) (if applicable) and The Author(s [打印本頁] 作者: 撕成碎片 時間: 2025-3-21 17:35
書目名稱Congenital Bleeding Disorders影響因子(影響力)
書目名稱Congenital Bleeding Disorders影響因子(影響力)學科排名
書目名稱Congenital Bleeding Disorders網(wǎng)絡公開度
書目名稱Congenital Bleeding Disorders網(wǎng)絡公開度學科排名
書目名稱Congenital Bleeding Disorders被引頻次
書目名稱Congenital Bleeding Disorders被引頻次學科排名
書目名稱Congenital Bleeding Disorders年度引用
書目名稱Congenital Bleeding Disorders年度引用學科排名
書目名稱Congenital Bleeding Disorders讀者反饋
書目名稱Congenital Bleeding Disorders讀者反饋學科排名
作者: Mnemonics 時間: 2025-3-21 21:57
Merete Christiansen,Carsten K. Hansenessment. On-demand therapy is the mainstay of treatment in VWD, although long-term prophylaxis is emerging for those with recurrent and severe bleeding. Therapeutic choices in VWD depend to some extent on geographical location, but include VWF/FVIII concentrates, recombinant VWF, and desmopressin.作者: 我還要背著他 時間: 2025-3-22 03:36 作者: nonsensical 時間: 2025-3-22 08:08
Christer J?nsson,Jonas Tallbergsma (FFP), plasma-derived FVII (pd-FVII), prothrombin complex concentrate (PCC), activated PCC (aPCC), and more recently, recombinant activated FVII (rFVIIa) are available for treatment of patients with FVII deficiency. New therapeutic options significantly improved the quality of life in patients with congenital FVII deficiency.作者: mitten 時間: 2025-3-22 11:19
https://doi.org/10.1007/978-3-030-60679-4aterial positive (CRM+). Different therapeutic choices are available, including fresh frozen plasma and FXI concentrate. However, plasma and factor XI concentrates can provoke inhibitor formation. Recombinant FVIIa treatment can be used for such patients.作者: Charlatan 時間: 2025-3-22 15:23
von Willebrand Disease: An Update on Diagnosis and Treatmentessment. On-demand therapy is the mainstay of treatment in VWD, although long-term prophylaxis is emerging for those with recurrent and severe bleeding. Therapeutic choices in VWD depend to some extent on geographical location, but include VWF/FVIII concentrates, recombinant VWF, and desmopressin.作者: Charlatan 時間: 2025-3-22 20:41 作者: 悠然 時間: 2025-3-22 21:30
Congenital Factor VII Deficiency, Diagnosis, and Managementsma (FFP), plasma-derived FVII (pd-FVII), prothrombin complex concentrate (PCC), activated PCC (aPCC), and more recently, recombinant activated FVII (rFVIIa) are available for treatment of patients with FVII deficiency. New therapeutic options significantly improved the quality of life in patients with congenital FVII deficiency.作者: 詳細目錄 時間: 2025-3-23 01:59 作者: OREX 時間: 2025-3-23 08:21 作者: 刺耳 時間: 2025-3-23 11:16 作者: 吞下 時間: 2025-3-23 14:06 作者: 關(guān)節(jié)炎 時間: 2025-3-23 21:12 作者: 得罪人 時間: 2025-3-24 00:58 作者: Lamina 時間: 2025-3-24 03:36
Congenital Bleeding Disorders: Diagnosis and Managementost CBDs (particularly IPFD) are mild bleeding disorders that seldom require medical intervention. The main therapeutic choice in most CBDs is on-demand therapy, while in others, such as severe cases of hemophilia A and B and FXIII deficiency, primary prophylaxis is the recommended treatment option.作者: Adenocarcinoma 時間: 2025-3-24 08:26 作者: 小蟲 時間: 2025-3-24 13:13 作者: 擴張 時間: 2025-3-24 15:26
Congenital Fibrinogen Disorders, Diagnosis, and Managementand the impact on the health-related quality of life. Fibrinogen supplementation is the mainstay of bleeding prevention and treatment. In this chapter, we propose an update on the classification, diagnosis, and management of hereditary fibrinogen disorders in several clinical settings.作者: 小蟲 時間: 2025-3-24 20:24
Congenital Prothrombin Deficiency: Diagnosis and Managementaboratory tests should be used for diagnosing FII deficiency. FII deficiency is suspected through prolonged prothrombin time (PT) and activate thromboplastin time (aPTT), which is confirmed by a specific FII assay. As no specific prothrombin concentrate is available, prothrombin complex concentrate 作者: languid 時間: 2025-3-25 01:27
Congenital Factor V Deficiency, Diagnosis, and Managementrothrombin time (PT) and activated thromboplastin time (aPTT). The diagnosis is confirmed by specific laboratory tests including FV antigen and activity assays. The only available therapeutic choice for patients with FV deficiency is fresh frozen plasma (FFP) in which the recommended dose is depende作者: 高興去去 時間: 2025-3-25 05:24
Combined Factor V and Factor VIII Deficiency, Diagnosis, and Managemente limited due to the unavailability of FV concentrates. Patients with F5F8D do not need lifelong hemostatic replacement therapy. Therapy is necessary upon spontaneous or traumatic bleeding, in the perioperative period, during pregnancy and delivery. When planning a family, it is necessary to take in作者: 別名 時間: 2025-3-25 09:52 作者: reperfusion 時間: 2025-3-25 14:35 作者: 集聚成團 時間: 2025-3-25 17:43 作者: 支柱 時間: 2025-3-25 23:13
Book 2023Latest editionld who have particular expertise in the disorder that they discuss. The book will be of value to hematologists, oncologists, pediatricians, laboratory specialists and technicians, general physicians, and trainees..作者: braggadocio 時間: 2025-3-26 02:50
Sergei M. Sitnik,Viktor I. Makovetskyost CBDs (particularly IPFD) are mild bleeding disorders that seldom require medical intervention. The main therapeutic choice in most CBDs is on-demand therapy, while in others, such as severe cases of hemophilia A and B and FXIII deficiency, primary prophylaxis is the recommended treatment option.作者: Amorous 時間: 2025-3-26 04:21
https://doi.org/10.1057/9781137349866e therapy is the only curative option, and it has recently been used successfully in selected hemophilia A patients. Current therapeutic options and supportive care significantly improve hemophilia A patients’ quality of life.作者: Painstaking 時間: 2025-3-26 10:52
https://doi.org/10.1057/9781137349866. However, inhibitor formation against FIX occurs up to 10% of the patients and represents a challenge because of the loss of efficacy of replacement therapy and the risk of severe allergic reactions. The use of recombinant FIX concentrates with extended half-life allows now for effective and safe t作者: Crohns-disease 時間: 2025-3-26 14:06
Determinants of Transnational Involvement,and the impact on the health-related quality of life. Fibrinogen supplementation is the mainstay of bleeding prevention and treatment. In this chapter, we propose an update on the classification, diagnosis, and management of hereditary fibrinogen disorders in several clinical settings.作者: 喃喃訴苦 時間: 2025-3-26 19:04 作者: 蟄伏 時間: 2025-3-26 21:20
Cecilia Lwiindi Nedziwe,Oluwaseun Tellarothrombin time (PT) and activated thromboplastin time (aPTT). The diagnosis is confirmed by specific laboratory tests including FV antigen and activity assays. The only available therapeutic choice for patients with FV deficiency is fresh frozen plasma (FFP) in which the recommended dose is depende作者: 戰(zhàn)役 時間: 2025-3-27 02:36
Transnational Actors in Global Governancee limited due to the unavailability of FV concentrates. Patients with F5F8D do not need lifelong hemostatic replacement therapy. Therapy is necessary upon spontaneous or traumatic bleeding, in the perioperative period, during pregnancy and delivery. When planning a family, it is necessary to take in作者: defibrillator 時間: 2025-3-27 08:13 作者: 多余 時間: 2025-3-27 10:04
https://doi.org/10.1057/978-1-137-48361-4ld bleeds, while in those with more severe hemorrhage, systemic hemostatic agents, including platelet concentrates and recombinant activated factor VII (rFVIIa), are used. Currently, platelet transfusion is the standard treatment, but repeated transfusions can result in alloimmunization and refracto作者: Armada 時間: 2025-3-27 15:00
An Overview of Hemostasisr injury. This process consists of three main components: the vascular system, cellular components, and non-cellular components. These work together closely to keep the circulatory system in the best condition..Hemostasis is divided into primary and secondary parts. In primary hemostasis, vascular e作者: 陰謀小團體 時間: 2025-3-27 19:30
Congenital Bleeding Disorders: Diagnosis and Management mostly in inherited platelet function disorders (IPFDs), to severe life-threatening disorders, notably in factor (F) XIII deficiency. Most of these disorders, which include rare bleeding disorders (RBD) and IPFD, are autosomal recessive disorders. Patients with hemophilia A and B typically have an 作者: 里程碑 時間: 2025-3-27 22:50
von Willebrand Disease: An Update on Diagnosis and Treatmentis classified into three main types: type 1 and type 3 as (respectively, partial and complete) quantitative deficiency of von Willebrand factor (VWF) and type 2 (with qualitative VWF defects). The bleeding tendency is highly variable, ranging from largely asymptomatic, mainly in mild type 1 VWD, to 作者: SPASM 時間: 2025-3-28 05:52
Hemophilia A: Diagnosis and Management male births, and is caused by a defect or deficiency in coagulation factor VIII (FVIII). Hemophilia A is caused by a variety of mutations in the FVIII gene, the most common of that is intron 22 inversion, which results in severe hemophilia A. The most frequent bleeding sites in hemophilia A patient作者: Limited 時間: 2025-3-28 07:24
Hemophilia B: Diagnosis and Managementence of ~1 per 30,000 males worldwide, around 3–4 fold less than hemophilia A. Patients with hemophilia B suffer from a bleeding tendency, usually related to the severity of factor deficiency. Recurrent joint bleeds, muscle, and soft-tissue hematoma are frequent in the severe deficiency (FIX <1?U/dL作者: ALB 時間: 2025-3-28 14:15
Congenital Fibrinogen Disorders, Diagnosis, and Managementype 2 (dysfibrinogenemia and hypodysfibrinogenemia). Classification of hereditary fibrinogen disorders is based not only on the activity (Clauss) and the antigenic fibrinogen levels but on the clinical features and the genotype as well. Diagnosis of dysfibrinogenemia can be challenging, as sensitivi作者: 假裝是我 時間: 2025-3-28 18:12 作者: 華而不實 時間: 2025-3-28 20:09 作者: SEVER 時間: 2025-3-28 23:14
Combined Factor V and Factor VIII Deficiency, Diagnosis, and Managementa simultaneous decrease of plasma FV and FVIII, usually between 5% and 30%, and is associated with a mild to moderate bleeding tendency. Women have more physiological conditions (menstrual cycle and delivery) for developing pathological bleeding. The bleeding phenotype of F5F8D is relatively similar作者: 使糾纏 時間: 2025-3-29 04:09 作者: 樹木中 時間: 2025-3-29 07:28 作者: pessimism 時間: 2025-3-29 11:37
Congenital Factor X Deficiency, Diagnosis, and Managementin the coagulation cascade. After activation, activated FX (FXa) is the first enzyme in the common coagulation pathway and plays a key role in thrombin generation. Congenital FX deficiency is a very rare bleeding disorder that is inherited in an autosomal recessive manner estimated to occur in 1:1,0作者: Endoscope 時間: 2025-3-29 16:43
Congenital Factor XI Deficiency, Diagnosis and Managementmillion in the general population, but in specific populations such as Ashkenazi Jews, the prevalence is as high as 1 per 450 individuals. FXI deficiency is a mild bleeding disorder mostly associated with post-traumatic or postsurgical hemorrhages or unexplained minor bleeding. Based on FXI activity作者: Calibrate 時間: 2025-3-29 19:52 作者: Resection 時間: 2025-3-30 01:43
Glanzmann Thrombasthenia: Diagnosis and Management (GP) IIb/IIIa). The disorder manifests with mucocutaneous bleeding early in life. Although purpura, epistaxis, gum bleeding, and menorrhagia are the most common clinical presentations, life-threatening hemorrhage can occur with fatal consequences. GT has a distinct laboratory feature with the absen作者: Nutrient 時間: 2025-3-30 05:31 作者: 先鋒派 時間: 2025-3-30 11:57 作者: leniency 時間: 2025-3-30 13:32
https://doi.org/10.1007/978-3-031-43156-2Common Bleeding Disorders; Von Willebrand Disorders; Hemophilia A; Hemophilia B; Rare Bleeding Disorders作者: GEON 時間: 2025-3-30 20:11
978-3-031-43158-6The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: creditor 時間: 2025-3-31 00:34 作者: 要素 時間: 2025-3-31 03:36 作者: AVID 時間: 2025-3-31 08:02
